How to Dose Caplyta (Lumateperone)
The recommended dosage of Caplyta is 42 mg once daily, taken orally with or without food, and no dose titration is required. 1
Standard Dosing for Adults
- Starting dose: 42 mg once daily
- Maintenance dose: 42 mg once daily
- Administration: Can be taken with or without food
- Titration: Not required—start at the therapeutic dose 1
This straightforward dosing applies to both FDA-approved indications: schizophrenia in adults and bipolar I or II depression (as monotherapy or adjunctive therapy with lithium or valproate) 1.
Dose Adjustments for Drug Interactions
When co-administering with CYP3A4 inhibitors, dose reduction is mandatory:
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): Reduce to 10.5 mg once daily 1
- Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, fluconazole): Reduce to 21 mg once daily 1
- CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort): Avoid concomitant use 1
These adjustments are critical because CYP3A4 inhibitors significantly increase lumateperone exposure, while inducers reduce efficacy.
Hepatic Impairment Dosing
For patients with moderate or severe hepatic impairment (Child-Pugh class B or C): Reduce dose to 21 mg once daily 1
No dose adjustment is needed for mild hepatic impairment. Renal impairment does not require dose modification.
Pediatric Considerations
Caplyta is NOT approved for use in pediatric patients. 1 The FDA labeling explicitly states that safety and effectiveness have not been established in children and adolescents, and the boxed warning emphasizes increased risk of suicidal thoughts and behaviors in young patients treated with antidepressants 1.
Note that while lurasidone (a different medication, not lumateperone/Caplyta) has been studied in adolescents with schizophrenia and bipolar depression at doses of 20-80 mg/day 2, 3, this does not apply to Caplyta, which is lumateperone, not lurasidone.
Important Clinical Considerations
Duration of adequate trial: Allow 4-6 weeks at therapeutic dose before assessing response, consistent with general antipsychotic treatment principles 4.
Common side effects to monitor:
- For schizophrenia: somnolence/sedation (24%) and dry mouth (6%) 1
- For bipolar depression: somnolence/sedation (13%), dizziness (8-11%), nausea (8-9%), and dry mouth (5%) 1
Metabolic advantages: Caplyta demonstrates minimal effects on weight, lipids, glucose, and prolactin—a significant advantage over many other antipsychotics 1.
Critical safety monitoring:
- Baseline and periodic assessment for extrapyramidal symptoms, though rates are low (6.7% vs 6.3% placebo) 1
- Monitor for orthostatic hypotension, particularly in elderly or those with cardiovascular disease 1
- Screen for tardive dyskinesia with long-term use 1
Elderly Patients
While no specific dose adjustment is mandated for age alone, exercise caution in elderly patients, particularly those with dementia-related psychosis (for whom Caplyta is contraindicated due to increased mortality risk) 1. Consider the 21 mg dose if hepatic impairment is present or if tolerability is a concern.
The simplicity of Caplyta's dosing—one dose for most patients, no titration required—represents a practical advantage in clinical practice, though vigilance for drug interactions and hepatic function remains essential.